Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 21.28 USD 0.9% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Kiniksa Pharmaceuticals Ltd?
Write Note

Kiniksa Pharmaceuticals Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kiniksa Pharmaceuticals Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Operating Income
-$26.2m
CAGR 3-Years
47%
CAGR 5-Years
32%
CAGR 10-Years
N/A
No Stocks Found

Kiniksa Pharmaceuticals Ltd
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The firm is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.

KNSA Intrinsic Value
28.26 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Kiniksa Pharmaceuticals Ltd's Operating Income?
Operating Income
-26.2m USD

Based on the financial report for Sep 30, 2024, Kiniksa Pharmaceuticals Ltd's Operating Income amounts to -26.2m USD.

What is Kiniksa Pharmaceuticals Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
32%

Over the last year, the Operating Income growth was -36%. The average annual Operating Income growth rates for Kiniksa Pharmaceuticals Ltd have been 47% over the past three years , 32% over the past five years .

Back to Top